Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
- The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
- The 143-patient Phase 2a trial demonstrated that IMC-1 met its primary endpoint of pain reduction and was statistically better tolerated than placebo.
- Reaching this enrollment milestone on a timely basis indicates that we are currently on track to report top line results in Q3 of 2022.
- Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.